These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 19901516)
21. Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population. Jung JW; Yoon SM; Kim S; Jeon YH; Yoon BH; Yang SG; Kim MK; Choe S; Kuo MM Oncotarget; 2016 Nov; 7(45):73754-73768. PubMed ID: 27650540 [TBL] [Abstract][Full Text] [Related]
22. Novel therapeutic strategies for targeting liver cancer stem cells. Oishi N; Wang XW Int J Biol Sci; 2011 Apr; 7(5):517-35. PubMed ID: 21552419 [TBL] [Abstract][Full Text] [Related]
23. RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF-β2. Wang X; Wang J; Tsui YM; Shi C; Wang Y; Zhang X; Yan Q; Chen M; Jiang C; Yuan YF; Wong CM; Liu M; Feng ZY; Chen H; Ng IOL; Jiang L; Guan XY Nat Commun; 2021 Mar; 12(1):1518. PubMed ID: 33750796 [TBL] [Abstract][Full Text] [Related]
24. ZnAs@SiO Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768 [No Abstract] [Full Text] [Related]
25. Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway. Wang X; Wang R; Bai S; Xiong S; Li Y; Liu M; Zhao Z; Wang Y; Zhao Y; Chen W; Billiar TR; Cheng B J Exp Clin Cancer Res; 2019 Dec; 38(1):505. PubMed ID: 31888685 [TBL] [Abstract][Full Text] [Related]
26. Notch3 functions as a regulator of cell self-renewal by interacting with the β-catenin pathway in hepatocellular carcinoma. Zhang Q; Lu C; Fang T; Wang Y; Hu W; Qiao J; Liu B; Liu J; Chen N; Li M; Zhu R Oncotarget; 2015 Feb; 6(6):3669-79. PubMed ID: 25668819 [TBL] [Abstract][Full Text] [Related]
27. Epigenetic downregulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats. Bagnyukova TV; Tryndyak VP; Muskhelishvili L; Ross SA; Beland FA; Pogribny IP Cell Cycle; 2008 Oct; 7(20):3202-10. PubMed ID: 18843197 [TBL] [Abstract][Full Text] [Related]
28. Hepatic Stellate Cells Contribute to the Tumor Malignancy of Hepatocellular Carcinoma Through the IL-6 Pathway. Iwahasi S; Rui F; Morine Y; Yamada S; Saito YU; Ikemoto T; Imura S; Shimada M Anticancer Res; 2020 Feb; 40(2):743-749. PubMed ID: 32014916 [TBL] [Abstract][Full Text] [Related]
29. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Majumdar A; Curley SA; Wu X; Brown P; Hwang JP; Shetty K; Yao ZX; He AR; Li S; Katz L; Farci P; Mishra L Nat Rev Gastroenterol Hepatol; 2012 Sep; 9(9):530-8. PubMed ID: 22710573 [TBL] [Abstract][Full Text] [Related]
31. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway. Ching RHH; Sze KMF; Lau EYT; Chiu YT; Lee JMF; Ng IOL; Lee TKW Oncotarget; 2017 Apr; 8(14):23507-23516. PubMed ID: 28186991 [TBL] [Abstract][Full Text] [Related]
32. FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells. Lin B; Chen T; Zhang Q; Lu X; Zheng Z; Ding J; Liu J; Yang Z; Geng L; Wu L; Zhou L; Zheng S Oncotarget; 2016 Nov; 7(47):77495-77507. PubMed ID: 27769048 [TBL] [Abstract][Full Text] [Related]
33. Cancer stem cells and epithelial-mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches. Fang D; Kitamura H Int J Urol; 2018 Jan; 25(1):7-17. PubMed ID: 28697535 [TBL] [Abstract][Full Text] [Related]
34. Restored expression of the tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma by suppressing Jagged1-Notch signaling. Nishina S; Shiraha H; Nakanishi Y; Tanaka S; Matsubara M; Takaoka N; Uemura M; Horiguchi S; Kataoka J; Iwamuro M; Yagi T; Yamamoto K Oncol Rep; 2011 Sep; 26(3):523-31. PubMed ID: 21637926 [TBL] [Abstract][Full Text] [Related]
35. Peroxiredoxin II Is Essential for Maintaining Stemness by Redox Regulation in Liver Cancer Cells. Kwon T; Bak Y; Park YH; Jang GB; Nam JS; Yoo JE; Park YN; Bak IS; Kim JM; Yoon DY; Yu DY Stem Cells; 2016 May; 34(5):1188-97. PubMed ID: 26866938 [TBL] [Abstract][Full Text] [Related]
36. Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways. Liu J; Chen S; Wang W; Ning BF; Chen F; Shen W; Ding J; Chen W; Xie WF; Zhang X Cancer Lett; 2016 Aug; 379(1):49-59. PubMed ID: 27216982 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214 [TBL] [Abstract][Full Text] [Related]
38. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway. Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383 [TBL] [Abstract][Full Text] [Related]
39. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits. Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422 [TBL] [Abstract][Full Text] [Related]
40. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways. Coulouarn C; Cavard C; Rubbia-Brandt L; Audebourg A; Dumont F; Jacques S; Just PA; Clément B; Gilgenkrantz H; Perret C; Terris B Carcinogenesis; 2012 Sep; 33(9):1791-6. PubMed ID: 22696594 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]